BioTuesdays

Category - Markets

Adicet Bio Logo
Markets

HCW starts Adicet Bio at buy; PT $27

H.C. Wainwright launched coverage of Adicet Bio (NASDAQ:ACET) with a “buy” rating and $27 price target. The stock closed at $13.11 on April 22. Adicet is focused on developing allogeneic gamma-delta T-cell therapies for...

April 23, 2021
cohbar-logo
Markets

Maxim starts CohBar at buy; PT $3

Maxim Group initiated coverage of CohBar (NASDAQ:CXBR), which is developing a therapeutic platform based on mitochondrial-derived peptides, with a “buy” rating and price target of $3. The stock closed at $1.24 on April...

April 23, 2021
Markets

Maxim ups Cerecor to buy from hold; PT $7

Maxim Group upgraded Cerecor (NASDAQ:CERC) to “buy” from “hold” with a price target of $7, citing an advancing pipeline of assets and the potential for multiple priority review vouchers (PRVs). The stock closed at $2.34...

April 21, 2021
89bio
Markets

Cantor starts 89bio at OW; PT $58

Cantor Fitzgerald launched coverage of 89bio (NASDAQ:ETNB) with an “overweight” rating and $58 price target. The stock closed at $25.81 on April 20. 89bio is developing BIO89-100, its injectable FGF21 hormone analog...

April 21, 2021
Markets

Maxim starts Fennec Pharma at buy: PT $12

Maxim Group initiated coverage of Fennec Pharmaceuticals (NASDAQ:FENC) with a “buy” rating and price target of $12. The stock closed at $6.27 on April 16. Fennec is developing PEDMARK, a unique formulation of sodium...

April 19, 2021
Lava-Therapeutics
Markets

SVB Leerink starts Lava Therapeutics at OP; PT $26

SVB Leerink launched coverage of Lava Therapeutics N.V. (NASDAQ:LVTX) with an “outperform” rating and $26 price target. The stock closed at $15 on April 16. Lava is at the leading edge of therapeutically targeting the...

April 19, 2021
111 inc logo
Markets

Citi transfers coverage of 111 Inc. with $16 PT

Citi Research transferred coverage of 111 Inc. (NASDAQ:YI) to Zoe Bian from Cui Cui, retaining a “buy/high risk” rating and price target of $16. Citi recently raised its price target to $16 from $12. The stock closed at...

April 19, 2021
exagen-diagnostics-logo
Markets

Canaccord starts Exagen at buy; PT $25

Canaccord Genuity launched coverage of Exagen (NASDAQ:XGN) with a “buy” rating and $25 price target. The stock closed at $16.69 on April 14. Analyst Max Masucci writes that Exagen provides a broad range of tests used to...

April 15, 2021